Berkongsi:
Rumah Sakit
Spesialisasi
Kualifikasi
- MBBS (UM, Malaysia)
- FRCR (UK)
- English
- Mandarin
- Malay
- Hokkien
- Kanker payudara
- Kanker serviks
- Kanker kolorektal
- Kanker saluran cerna
- Karsinoma hepatoseluler
- Kanker hati
- Kanker paru-paru
- Kanker ovarium
- Kanker prostat
- Kanker rahim
- 2023 - present : Breast working group, The Federation of Asian Organisations for Radiation Oncology. Current project : FERN-BR-001(WG:Breast/Health Economics), Burden of Financial toxicity in breast cancer patients treated with curative intent: a multinational study from low middle income countries
- 2023 – present : Lead country coordinator for The International Atomic Energy Agency (IAEA) project : RAS6110, "Improving the Radiotherapy Capacity of Newcomer Government Parties (RCA)"
- Member of Royal college of radiologist (RCR)
- Member of European society of medical oncology (ESMO)
- Member of European society for radiotherapy and oncology (ESTRO)
- Co-investigator of “ Phase III , open-label, randomized study of Atezolizumab in combination with Carboplatin or Cisplatin + Premetrexed compared with Carboplatin or Cisplatin + Premetrexed in patients who are chemotherapy-naive and have stage IV non squamous non-small cell lung cancer. IMpower132 Trial (2017)
- Co-investigator of “ Phase III, multicenter, randomized, placebo-controlled study of Atezolizumab as monotherapy and in combination with Platinum-based chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma. IMvigor130 (2017)
- Co-investigator of “ Randomized, double blind, placebo-controlled phase III clinical trial of Pembrolizumab in combination with Cisplatin and 5-Fluorouracil versus placebo in combination with Cisplatin and 5-Fluorouracil as first-line treatment in subjects with advanced/metastatic esophageal carcinoma. KEYNOTE-975 (2018)
- Co-investigator of “Phase 3, open-label, randomised, non-inferiority International randomised study of prostatectomy vs stereotactic body radiotherapy (SBRT) and conventional radiotherapy vs SBRT for organ-confined prostate cancer.” PACE-B (2020)
- Principal investigator of “A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, and Immunogenicity of AP063 to Herceptin® in Subjects with HER2+ Breast Cancer” Protocol Number: AP063-003 (2024)
- Principal investigator of “A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy” eVOLVE-HNSCC (2024)
- Principal investigator of “A Randomized, Double-Blind Study to compare Efficacy, Safety and Pharmacokinetics between ABP 234 and Pembrolizumab (Keytruda) in Subjects with Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer” Protocol Number: 20210033 (2024)
- Time management: Improving the timing of post-prostatectomy radiotherapy, clinical trials, and knowledge translation. Kai Yun Ooi, Ian Pereira, Himanshu Nagar, Richard Simcock, Matthew S Katz, Christopher C Parker, Colleen Lawton, Hina Saeed. Clinical and Translational Radiation Oncology Journal (2021)
- A retrospective audit into the prophylactic use of antibiotics in patients receiving chemotherapy for lung cancer. Cathryn Crockett, Hasanthi Nillegoda, Kai Yun Ooi and Margaret Harris. Poster abstracts of the 19th Annual British Thoracic Oncology Group Conference 2021
| Senin | 08:30 - 13:00 & 14:00 - 17:00 |
| Selasa | 08:30 - 13:00 & 14:00 - 17:00 |
| Rabu | 08:30 - 13:00 & 14:00 - 17:00 |
| Kamis | 08:30 - 13:00 & 14:00 - 17:00 |
| Jumat | 08:30 - 13:00 & 14:00 - 17:00 |
| Sabtu | 08:30 - 13:00 |
Pertanyaan - Dr. Ooi Kai Yun - Icon Cancer Centre
